Report Detail
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2019-2024
- RnM3064480 |
- 06 March, 2019 |
- Global |
- 132 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
According to this study, over the next five years the Glucagon Like Peptide-1 (GLP-1) Agonists market will register a 14.3% CAGR in terms of revenue, the global market size will reach US$ 11700 million by 2024, from US$ 5240 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Glucagon Like Peptide-1 (GLP-1) Agonists business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists market by product type, application, key manufacturers and key regions and countries.
This study considers the Glucagon Like Peptide-1 (GLP-1) Agonists value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Glucagon Like Peptide-1 (GLP-1) Agonists consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Glucagon Like Peptide-1 (GLP-1) Agonists market by identifying its various subsegments.
Focuses on the key global Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Glucagon Like Peptide-1 (GLP-1) Agonists with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Glucagon Like Peptide-1 (GLP-1) Agonists submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption 2014-2024
- 2.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Consumption CAGR by Region
- 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
- 2.2.1 Exenatied
- 2.2.2 Liraglutide
- 2.2.3 Lixisenatide
- 2.2.4 Albiglutide
- 2.2.5 Dulaglutide
- 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Type
- 2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Type (2014-2019)
- 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
- 2.4.1 Hospital
- 2.4.2 Pharmacy
- 2.4.3 Other
- 2.5 Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
- 2.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Value and Market Share by Application (2014-2019)
- 2.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Application (2014-2019)
3 Global Glucagon Like Peptide-1 (GLP-1) Agonists by Players
- 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Players
- 3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Players (2017-2019)
- 3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Players (2017-2019)
- 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Players
- 3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Players (2017-2019)
- 3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Players (2017-2019)
- 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sale Price by Players
- 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Glucagon Like Peptide-1 (GLP-1) Agonists by Regions
- 4.1 Glucagon Like Peptide-1 (GLP-1) Agonists by Regions
- 4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Regions
- 4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Value by Regions
- 4.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Growth
- 4.3 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Growth
- 4.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Growth
- 4.5 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Growth
5 Americas
- 5.1 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries
- 5.1.1 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries (2014-2019)
- 5.1.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Value by Countries (2014-2019)
- 5.2 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Type
- 5.3 Americas Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries
- 6.1.1 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries (2014-2019)
- 6.1.2 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Value by Countries (2014-2019)
- 6.2 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Type
- 6.3 APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 7.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries (2014-2019)
- 7.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Value by Countries (2014-2019)
- 7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Type
- 7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 8.1.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Value by Countries (2014-2019)
- 8.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Type
- 8.3 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
- 10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customer
11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast
- 11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2019-2024)
- 11.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Regions
- 11.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Regions (2019-2024)
- 11.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Type
- 11.8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecast by Application
12 Key Players Analysis
- 12.1 Novo Nordisk
- 12.1.1 Company Details
- 12.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 Novo Nordisk News
- 12.2 AstraZeneca
- 12.2.1 Company Details
- 12.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 AstraZeneca News
- 12.3 Eli Lilly
- 12.3.1 Company Details
- 12.3.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.3.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Eli Lilly News
- 12.4 GSK
- 12.4.1 Company Details
- 12.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 GSK News
- 12.5 Sanofi
- 12.5.1 Company Details
- 12.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Sanofi News
- 12.6 Bristol-Myers Squibb
- 12.6.1 Company Details
- 12.6.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Bristol-Myers Squibb News
- 12.7 Amylin
- 12.7.1 Company Details
- 12.7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered
- 12.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Amylin News
...
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Glucagon Like Peptide-1 (GLP-1) Agonists . Industry analysis & Market Report on Glucagon Like Peptide-1 (GLP-1) Agonists is a syndicated market report, published as Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
